New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:15 EDTTEVAFDA approves expanded label for Teva's Azilect
Teva Pharmaceutical Industries announced the U.S. Food and Drug Administration has expanded the indication for AZILECT from monotherapy and adjunct to levodopa to now include adjunct to dopamine agonists. The new indication reflects that AZILECT can be used alone or in combination with other Parkinson's disease medications. The approval reinforces the growing clinical evidence demonstrating the benefit of AZILECT across all stages of PD. The FDA approval of the expanded label is based on a supplemental new drug application submitted by Teva, supported by data from the ANDANTE study. The study demonstrated AZILECT provides a clinical benefit by significantly improving total Unified Parkinson's Disease Rating Scale scores compared to placebo in patients on DA monotherapy, while demonstrating tolerability.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research
October 9, 2014
16:11 EDTTEVAAlexza reports 32,278 Adasuve units shipped to Teva in Q3
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use